TPN bag (patient specific), 1660 mL recall — Central Admixture Pharmacy Services, Inc (caps) Los Angeles (Class II)
Central Admixture Pharmacy Services, Inc (caps) Los Angeles is recorded by the U.S. Food and Drug Administration (FDA) as recalling TPN bag (patient specific), 1660 mL — a Class II recall, initiated 2025-12-27 and posted to the FDA enforcement report on 2026-05-13, under recall number D-0524-2026. Status Ongoing, with no termination date on the record. The reason the FDA record carries is, verbatim: “Incorrect Product Formulation: product did not contain insulin as listed in the label.”. From the product description, the form is injection, the strength given is 1660 mL and it is marked Rx only. Distribution is recorded as “CA” — Limited / regional distribution, with the recalling firm on record in CA, United States. It is the only recall number the FDA has filed under event ID 98831. Values are reproduced from the linked openFDA report; regulatory information, not medical advice.
Regulatory snapshot
| Recall number | D-0524-2026 |
|---|---|
| FDA event ID | 98831 |
| Classification | Class II (intermediate regulatory tier) |
| Status | Ongoing |
| Recalling firm | Central Admixture Pharmacy Services, Inc (caps) Los Angeles |
| Recall initiated | 2025-12-27 |
| Reported by FDA | 2026-05-13 |
| Report lag | 137 days from initiation to report |
| Distribution | CA — Limited / regional distribution |
| Firm location on record | CA, United States |
| Product description (source) | TPN bag (patient specific), Rx# 11-4909703-0-1, Compound Volume 1660 mL per bag, Rx only, Single Dose Injection, Refrigerated Injection, Central Admixture Pharmacy Services, Los Angeles, 13128 Imperial Hwy, Santa Fe Spr., CA 90670 |
Reason reported by FDA
Incorrect Product Formulation: product did not contain insulin as listed in the label.
13 words from the enforcement report field reason_for_recall, reproduced without edit — the firm's own wording, not an assessment.
Product identifiers in this record
3 identifying values matched by exact pattern in the 33-word product description above; each is a literal substring of it.
| Product named | TPN bag (patient specific) |
|---|---|
| Form | Injection |
| Strength | 1660 mL |
| Marketing category | Rx only |
Reported in the same month (2026-05)
48 enforcement reports carry a report date in 2026-05; these 8 are the Class II ones nearest this record.
| Recall record | Recall number | Recalling firm | FDA tier | Reported |
|---|---|---|---|---|
| DELFLEX, 1.5% | D-0512-2026 | Fresenius Medical Care Holdings, Inc. | Class II | 2026-05-13 |
| DELFLEX, 2.5% | D-0513-2026 | Fresenius Medical Care Holdings, Inc. | Class II | 2026-05-13 |
| Duloxetine Delayed-Release Capsules, 30 mg | D-0514-2026 | Ajanta Pharma Ltd. | Class II | 2026-05-13 |
| Duloxetine Delayed-Release Capsules, 60 mg | D-0515-2026 | Ajanta Pharma Ltd. | Class II | 2026-05-13 |
| Duloxetine Delayed-Release Capsules, 20 mg | D-0516-2026 | Ajanta Pharma Ltd. | Class II | 2026-05-13 |
| BD PurPrep, 8.3% | D-0517-2026 | Carefusion 213, LLC | Class II | 2026-05-13 |
| BD PurPrep, 8.3% | D-0518-2026 | Carefusion 213, LLC | Class II | 2026-05-13 |
| Octreotide Acetate for Injectable Suspension, 30 mg | D-0519-2026 | Teva Pharmaceuticals Usa, Inc | Class II | 2026-05-13 |
Nearest Class II recalls by date
213 of 250 indexed records share the Class II tier; the 8 nearest to 2026-05-13 by report date are listed here.
| Recall record | Recall number | Recalling firm | Strength / form | Reported |
|---|---|---|---|---|
| Enalapril Maleate Tablets, 20 mg | D-0520-2026 | JB Chemicals And Pharmaceuticals Ltd | 20 mg · Tablets | 2026-05-13 |
| Duloxetine Delayed-Release Capsules USP, 60mg | D-0522-2026 | Breckenridge Pharmaceutical, Inc. | 60mg · Delayed-Release Capsules | 2026-05-13 |
| NAPROXEN ORAL SUSPENSION, 125 mg/5mL | D-0523-2026 | Acella Pharmaceuticals, LLC | 125 mg/5mL · Oral Suspension | 2026-05-13 |
| Systane, 10g | D-0491-2026 | Alcon Research LLC | 10g · Gel | 2026-05-06 |
| GenTeal Tears, 10g | D-0492-2026 | Alcon Research LLC | 10g · Gel | 2026-05-06 |
| Optase Dry Eye Intense Drops (Glycerin 0.2%) | D-0499-2026 | Scope Health | 0.2% · Drops | 2026-05-06 |
| iVIZIA, 0.5% | D-0500-2026 | Thea Pharma, Inc. | 0.5% · Eye Drops | 2026-05-06 |
| Similasan, 0.5% | D-0501-2026 | Thea Pharma, Inc. | 0.5% · Eye Drops | 2026-05-06 |
Reading this record
Class II is the FDA's own severity tier for the recall action — 213 of the 250 indexed records carry it — and it describes the agency's assessment of the action, not a risk statement about any individual.
Namespace context: the Class II index (213 records) and the recall hub (250 records, 118 FDA events); Central Admixture Pharmacy Services, Inc (caps) Los Angeles (1 indexed records) aggregates this firm across datasets.
Coverage and limits of this record
This page reflects the openFDA enforcement report for D-0524-2026 as ingested on 2026-08-22, which can lag the live FDA record and omits detail held only in primary documents. It offers no clinical assessment, no advice about whether to use any product, and no substitute. For any health question consult a qualified healthcare professional.
Source & provenance
- Official source
- https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0524-2026%22
- Source dataset
- openFDA Drug Enforcement API
- Publication date
- 2026-05-13
- Ingested
- 2026-08-22
- Record hash
99b7035e92d5078b
Verify every value against the official FDA source above. This site links to the regulator's record rather than replacing it.